Exploiting the healthy microflora to develop new treatments for Staphylococcus pseudintermedius infection in canine atopic dermatitis
dc.contributor.advisor
Paterson, Gavin
dc.contributor.advisor
Nuttall, Timothy
dc.contributor.author
Newstead, Logan
dc.contributor.sponsor
PetSavers
en
dc.date.accessioned
2024-07-03T15:09:48Z
dc.date.available
2024-07-03T15:09:48Z
dc.date.issued
2020-12-15
dc.description.abstract
Staphylococcus pseudintermedius is a commensal microorganism and opportunistic pathogen, most frequently responsible for causing pyoderma and secondary skin infections in dogs with atopic dermatitis, one of the most common causes for antimicrobial prescriptions in small animal practice. The emergence of methicillin- and multidrug-resistant S. pseudintermedius strains has resulted in some infections being deemed untreatable by many veterinarians. The potential for zoonotic transmission also makes S. pseudintermedius a public health concern; thus, identifying novel antimicrobial treatments for S. pseudintermedius is a priority in human and animal health.
Bacteriocins, ribosomally-synthesised peptides, provide an alternative to antibiotics, displaying potent, specific, antimicrobial activity against strains closely related to or sharing the same niche as the producing bacteria.
This study explored the skin microbiota of healthy dogs, investigating the prevalence of commensal staphylococci, and bacteriocin production by the species isolated.
Staphylococci were isolated from skin swabs of 121 healthy dogs; 166 isolates, belonging to 20 species, including two proposed novel species, were identified.
Twelve methicillin-resistant isolates were identified, seven of which were multidrug-resistant, all belonging to coagulase-negative staphylococci species.
Thirteen isolates belonging to eight species displayed inhibitory activity against S. pseudintermedius via deferred-antagonism assay. One Staphylococcus devriesei isolate, H14, inhibited ten clinically relevant S. pseudintermedius and two Staphylococcus aureus strains in cell- free supernatant assays, reducing growth by over 70%, including methicillin-resistant strains. Genome-mining identified two novel bacteriocin gene clusters from S. devriesei H14. Nine further novel bacteriocin gene clusters were identified, from S. pseudintermedius, Staphylococcus warneri, Staphylococcus simulans, and Staphylococcus xylosus. These bacteriocins show promise as novel therapies for S. pseudintermedius infections in canine atopic dermatitis.
en
dc.identifier.uri
https://hdl.handle.net/1842/41949
dc.identifier.uri
http://dx.doi.org/10.7488/era/4672
dc.language.iso
en
en
dc.publisher
The University of Edinburgh
en
dc.subject
bacteriocins
en
dc.subject
antimicrobial peptides
en
dc.subject
Staphylococcus
en
dc.subject
Staphylococcus aureus
en
dc.subject
MRSA
en
dc.title
Exploiting the healthy microflora to develop new treatments for Staphylococcus pseudintermedius infection in canine atopic dermatitis
en
dc.type
Thesis or Dissertation
en
dc.type.qualificationlevel
Masters
en
dc.type.qualificationname
MSc(R) Master of Science by Research
en
Files
Original bundle
1 - 1 of 1
- Name:
- NewsteadL_2020.pdf
- Size:
- 4.47 MB
- Format:
- Adobe Portable Document Format
- Description:
- MSc(R)
This item appears in the following Collection(s)